Tirzepatide - Informational Research Article: Scientific & Clinical Overview

Regulatory status

Tirzepatide is an active pharmaceutical substance that has completed an extensive clinical development program. Regulatory authorization applies to specific medicinal products, manufacturers, formulations, indications, and jurisdictions — not to every material that contains tirzepatide.

In the European Union, Mounjaro, whose active substance is tirzepatide, holds a centralized marketing authorization granted on 15 September 2022; the marketing authorization holder is Eli Lilly Nederland B.V. As recorded by the European Medicines Agency, the authorized indications are, for type 2 diabetes, treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise; and, for weight management, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial BMI of at least 30 kg/m² (obesity), or from 27 to under 30 kg/m² (overweight) with at least one weight-related comorbid condition. Authorized indications and product names differ between jurisdictions; current FDA labeling should be consulted for the United States.

Important regulatory distinction. The existence of a marketing authorization for a branded medicine containing a given active substance does not establish the approval, equivalence, quality, safety, or efficacy of any other material that happens to contain the same substance.

Clinical research

Major published Phase 2 and Phase 3 trials are summarized below. Doses named describe how the trials were designed; they are not dosing instructions.

SURPASS-2 — type 2 diabetes, head-to-head vs semaglutide (Phase 3). A 40-week, randomized, open-label trial in 1,879 adults with type 2 diabetes (mean baseline HbA1c 8.28%), comparing tirzepatide 5/10/15 mg with semaglutide 1 mg once weekly. Reported HbA1c change was approximately −2.01, −2.24 and −2.30 percentage points for tirzepatide 5/10/15 mg versus −1.86 for semaglutide; body-weight change was approximately −7.6, −9.3 and −11.2 kg versus −5.7 kg. Frias JP, et al. N Engl J Med. 2021;385:503–515.

SURMOUNT-1 — obesity, without diabetes (Phase 3). A 72-week, randomized, double-blind, placebo-controlled trial in 2,539 adults with obesity (or overweight with a complication), without diabetes. At week 72 the reported mean body-weight change (treatment-policy estimand) was approximately −15.0%, −19.5% and −20.9% for tirzepatide 5/10/15 mg versus −3.1% for placebo; under the efficacy estimand, mean reductions reached up to about 22.5% in the highest-dose group. In the 10 mg and 15 mg groups, roughly 50% and 57% of participants reached at least 20% weight reduction versus about 3% with placebo. Jastreboff AM, et al. N Engl J Med. 2022;387:205–216.

SURMOUNT-4 — weight maintenance (Phase 3, randomized withdrawal). After a 36-week open-label lead-in, participants continued tirzepatide or switched to placebo. From week 36 to week 88 the reported change was an additional ~−5.5% with continued treatment versus ~+14.0% regain on placebo; roughly 89.5% versus 16.6% maintained at least 80% of the weight initially lost. Aronne LJ, et al. JAMA. 2024;331:38–48.

SURMOUNT-5 — obesity, head-to-head vs semaglutide (Phase 3b). A 72-week randomized trial in 751 adults with obesity without diabetes, comparing the maximum tolerated dose of tirzepatide (10/15 mg) with that of semaglutide (1.7/2.4 mg). Reported mean body-weight change was approximately −20.2% with tirzepatide versus −13.7% with semaglutide at week 72, with a greater reduction in waist circumference (about −18.4 vs −13.0 cm). Aronne LJ, et al. N Engl J Med. 2025 (PMID 40353578).

SURMOUNT-OSA — obstructive sleep apnea with obesity (Phase 3). Two 52-week, placebo-controlled trials (with and without positive airway pressure therapy) in adults with moderate-to-severe obstructive sleep apnea and obesity. The apnea-hypopnea index decreased by about 25.3 events/hour with tirzepatide versus 5.3 with placebo in the first trial, and by about 29.3 versus 5.5 in the second; trials also reported changes in body weight, hypoxic burden, high-sensitivity C-reactive protein and systolic blood pressure. Regulatory status varies by jurisdiction: in the United States the FDA has approved the tirzepatide-containing medicine Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024); that authorization applies to the approved medicinal product and its labeled indication. Malhotra A, et al. N Engl J Med. 2024;391:1193–1205.

SYNERGY-NASH — metabolic dysfunction-associated steatohepatitis (Phase 2). A 52-week, double-blind, placebo-controlled, dose-finding trial in 190 participants with biopsy-confirmed MASH and F2/F3 fibrosis. MASH resolution without worsening of fibrosis occurred in approximately 10% (placebo), 44% (5 mg), 56% (10 mg) and 62% (15 mg) in the primary analysis. As a Phase 2 study, this establishes a signal that requires larger and longer Phase 3 trials to confirm. Loomba R, et al. N Engl J Med. 2024;391:299–310.

SUMMIT — heart failure with preserved ejection fraction and obesity (Phase 3). A randomized, placebo-controlled trial in 731 participants over a median of about two years. The composite of cardiovascular death or a worsening heart-failure event occurred less often with tirzepatide than placebo (about 9.9% vs 15.3%; hazard ratio 0.62, 95% CI 0.41–0.95), driven mainly by fewer worsening heart-failure events; the difference in cardiovascular death alone did not reach statistical significance. Health-status scores (KCCQ) improved relative to placebo. Packer M, et al. N Engl J Med. 2025;392:427–437.

Clinical evidence matrix

Figures are as reported in the primary publications and should be verified against those sources.

Clinical development timeline

• 2016–2019 — early-phase (Phase 1/2) clinical development of LY3298176.
• 2021 — SURPASS Phase 3 program in type 2 diabetes reported, including the SURPASS-2 comparison with semaglutide.
• 2022 — SURMOUNT-1 obesity results published; EMA marketing authorization for Mounjaro (15 September 2022).
• 2023–2024 — weight-maintenance evidence (SURMOUNT-4); expansion into sleep apnea (SURMOUNT-OSA) and metabolic liver disease (SYNERGY-NASH, Phase 2).
• 2024–2025 — cardiometabolic evidence in HFpEF with obesity (SUMMIT) and the head-to-head obesity comparison (SURMOUNT-5).

Limitations and interpretation

• Trials use specific inclusion/exclusion criteria; results do not necessarily generalize to everyone.
• Interventions were regulated pharmaceutical products made to defined standards; data do not establish equivalence of other materials.
• Trial durations are finite; long-term outcomes beyond the studied periods are not established by these trials alone.
• Secondary and exploratory outcomes carry less certainty than primary endpoints; Phase 2 signals need Phase 3 confirmation.
• Because many secondary metabolic outcomes accompany substantial weight loss, direct drug effects are difficult to isolate.
• Most trials were industry-sponsored, which should be disclosed when interpreting the results.

How incretin mechanisms differ

This comparison is mechanistic and informational; it is not advice on which agent to use. Tirzepatide is a dual agonist of the GIP and GLP-1 receptors. Semaglutide is a GLP-1 receptor agonist acting on a single incretin pathway. Cagrilintide acts on the amylin pathway and is studied, including in combination regimens, as a separate mechanistic approach.